Thursday, August 29, 2013

Moody's Puts RBS Under Review - Analyst Blog

Best Undervalued Stocks To Watch Right Now

Moody's Investors Service – a rating arm of Moody's Corporation (MCO) – kept the long-term ratings on The Royal Bank of Scotland Group plc (RBS) and its subsidiaries under review for downgrade. The rating agency cited the British government's decision of a possible break-up of the bank as the reason behind its action.

Currently, The Royal Bank of Scotland – a subsidiary of The Royal Bank of Scotland Group plc – has a long-term debt and deposit rating of "A3" and a standalone bank financial strength rating of "D+", both of which have been placed under review.

Additionally, Moody's placed the standalone credit assessments and all other long-term ratings of The Royal Bank of Scotland's subsidiaries – National Westminster Bank (Natwest) plc and Royal Bank of Scotland NV – under review.

Concurrently, Moody's subjected the long-term debt and deposit ratings of Ulster Bank Limited and Ulster Bank Ireland Limited and the ratings of the banks' subordinated debt instruments to review. Ulster Bank's short-term ratings are to be reviewed as well. Moody's expectation of the break-up of The Royal Bank of Scotland by the government might affect the bank's capability of offering support to these Northern Ireland institutions.

Reason Behind Downgrade

Moody's stated that the revision of the ratings was due to the British government's decision to evaluate the breaking up of The Royal Bank of Scotland, and moving off its problematic assets into a separate bank. The British government had bailed out The Royal Bank of Scotland for a sum of almost £45 billion in 2008, making it the costliest bank bailout in history. However, the British Treasury is struggling to reduce its 81% stake in the bank, with its shares trading for a lesser price than the government paid for them.

The rating agency believes that the ! government's review of the troubled bank will create more uncertainty for bond holders. Additionally, according to Moody's, the government decision to shed the high risk and/or impaired assets from the bank may involve losses for creditors.

Our Viewpoint

Initially, the British government was commended for its efforts in dealing with the financial crisis in 2007. The government bailed out as well as attained large stakes in The Royal Bank of Scotland and Lloyds Banking, as well as several other smaller banks.

However, almost 5 years after the bailout, the extensive practice of restructuring the troubled banks is putting the weak British economy under pressure. This is partly due to the government's decision in 2008 to take a passive approach to managing its stakes in the deeply troubled banks. Anticipating the banks' quick return to their private ownerships, the government did not to intrude into their strategies.

Among such banks, one was The Royal Bank of Scotland, which continued for years since the economic crisis without restructuring its troubled and non-profitable units, forcing the government to contemplate a split. However, the bank's low share price means that a sale would likely cause taxpayers losses worth billions of pounds.

However, we expect The Royal Bank of Scotland's diversified business model and sound financial position to contribute to its overall growth in the future.

The Royal Bank of Scotland currently carry a Zacks Rank #3 (Hold). Some better performing foreign banks include Mitsubishi UFJ Financial Group, Inc. (MTU) and Sumitomo Mitsui Financial Group Inc. (SMFG). Both the stocks carry a Zacks Rank #1 (Strong Buy).


Wednesday, August 28, 2013

PartnerRe Dipped to Neutral - Analyst Blog

On Jul 11, we downgraded global life and property-casualty (P&C) insurer and reinsurer – PartnerRe Ltd. (PRE) – to Neutral based on its weak investment portfolio and high competition. While the Presidio acquisition diversifies the company's product profile, it brings in additional costs that will weigh on margins at least for some time.

Why the Downgrade?

Estimates for PartnerRe witnessed modest corrections after the company reported its first-quarter 2013 results on Apr 29, wherein earnings stood at $3.39 per share. Earnings per share outpaced both the Zacks Consensus Estimate and year-ago number of $2.47 and $2.76, respectively. Overall, PartnerRe delivered positive earnings surprises in all of the last 4 quarters with an average beat of 151.1%.

However, total revenue edged down 2.6% year over year to $1.3 billion and was almost in line with the Zacks Consensus Estimate. Growth from premiums written was more than offset by lower investment income.

While total expenses surged 13%, combined ratio improved to 81.7% from 84.7% in the year-ago period. In addition, technical results and underwriting profitability improved, driving growth in bottom line, book value per share and return on equity (ROE).

Following the release of the first-quarter results, the Zacks Consensus Estimate for 2013 inched up 1.8% to $9.25 per share in the last 60 days. Moreover, the Zacks Consensus Estimate for 2014 edged up about 1.0% to $8.11 per share in the last 60 days.

With the Zacks Consensus Estimates for both 2013 and 2014 exhibiting no clear directional pressure in the near term and estimates for both the years posing year-over-year deterioration, PartnerRe now has a Zacks Rank #3 (Hold).

Cause for Concern

The recent acquisition of Presidio not only drove the premiums of PartnerRe but also helped the company diversify. Presidio's robust market presence and expert management should further strengthen the company's fundamentals. However, concerns ling! er over the sustainability of this growth amid the weak P&C market and a history of challenges faced in the integration of ParisRe.

Moreover, intense competition, currency fluctuations, weak credit spreads and low interest rate environment have restricted investment income and yields, thereby limiting the desired upsides. Nevertheless, PartnerRe enjoys above-average liquidity and a low-risk balance sheet, which is reflected in its consistent and efficient capital deployment. In the long run, a stable ratings outlook, improved pricing and market stability can help mitigate the cyclical declines.

Other Insurers That Warrant a Look

While we prefer to avoid PartnerRe until we gain more clarity on the stock's performance, other P&C insurers and reinsurers that are worth a look are AmTrust Financial Services Inc. (AFSI), HCI Group Inc. (HCI) and American Safety Insurance Holdings Inc. (ASI). All these stocks carry a Zacks Rank #1 (Strong Buy).

Top Tech Stocks To Watch Right Now

In the future, Amazon (NASDAQ: AMZN  ) could find itself in a bit of a pickle. The company has been increasing costs faster than it can grow revenues, which, over the long term, is an unsustainable trend. A lot of the blame has been placed on Amazon Prime, despite being attributed with driving increased spending with members.

Last quarter, fulfillment costs rose more than 38% year over year, and technology and content costs rose 46%; yet total sales only grew by 22%. In other words, the short-term costs associated with running Amazon Prime appear to be far greater than the short-term benefit. Investors continue to justify this unsustainable trend because the company has made it clear that growth is currently a higher priority than profitability.

Quite frankly, investors are correct for making the assumption that profitability will come at a later time.

Top Tech Stocks To Watch Right Now: Modena Resources Ltd (MDA.AX)

Sprint Energy Limited engages in the exploration and production of oil and gas properties in the United States. It primarily owns interests in various onshore leases located on Padre Island, and in Hidalgo and Starr counties. The company was formerly known as Modena Resources Limited and changed its name to Sprint Energy Limited in December 2011. Sprint Energy Limited is based in St Kilda, Australia.

Top Tech Stocks To Watch Right Now: The Intergroup Corporation(INTG)

The Intergroup Corporation, through its subsidiaries, engages in the operation of a hotel located in San Francisco, California. Its hotel comprises 544 rooms with 5,400 square feet of space for the operation of health and beauty spa. The company also involves in the ownership, management, and sale of real estate properties. Its property portfolio includes 18 apartment complexes, 2 commercial real estate properties, and 2 single-family houses in Texas and southern California. In addition, the company owns two unimproved real estate properties located in Austin, Texas, and Maui, Hawaii. The Intergroup Corporation was founded in 1965 and is based in Los Angeles, California.

Best China Companies For 2014: ASF Group Ltd(AFA.AX)

ASF Group Limited, an investment company, operates in the resources, property, travel, commodities, infrastructure, and financial services sectors in Australia and China. The company holds interests in various mineral exploration projects, including the South Ellendale thermal coal and diamonds project covering an area of approximately 2,000 square kilometers in the Canning Basin of Western Australia; and two mineral exploration ventures for base metals and gold in Tasmania. It also involves in the shipping of bulk commodities from Australia to markets in China; development of port and rail facilities; and provision of property services to Chinese investors in Australia, as well as provides funds management and advisory services. ASF Group Limited was founded in 1980 and is headquartered in Sydney, Australia.

Monday, August 26, 2013

Is SunPower a Worthwhile Risk?

With shares of SunPower Corporation (NASDAQ:SPWR) trading at around $15.18, is SPWR an OUTPERFORM, WAIT AND SEE or STAY AWAY? Let's analyze the stock with the relevant sections of our CHEAT SHEET investing framework:

C = Catalyst for the Stock's Movement

SunPower has seen a lot of volatility lately. This has a lot to do with SunPower being one of the top players in a weak industry. Many longs like the company, and many shorts hate the industry. Let's take a look at some positives and negatives for SunPower.

Positives:

Most efficient solar panels in industry (residential) Strong performance from rooftop and ground mount teams Consistently improving revenues on an annual basis Strong revenue growth in Americas and Asia-Pacific Gross margin expansion Improved cash flow Increased demand Residential lease growth Cost structure improvements Analysts like the stock (kind of): 4 Buy, 11 Hold, 3 Sell

Negatives:

Consistent losses Revenue declines in Europe, Middle East, and Africa Increased competition Foreign exchange risks

Now let's take a look at some numbers. The chart below compares fundamentals for SunPower, First Solar (NASDAQ:FSLR), and Trina Solar (TSLR). SunPower has a market cap of $1.81 billion, First Solar has a market cap of $3.79 billion, and Trina Solar has a market cap of $387.69 million.

NEW! Discover a new stock idea each week for less than the cost of 1 trade. CLICK HERE for your Weekly Stock Cheat Sheets NOW!

SPWR

FSLR

TSL

Trailing   P/E

N/A

N/A

N/A

Forward   P/E

26.65

13.36

N/A

Profit   Margin

-12.98%

-2.86%

-20.56%

ROE

-31.00%

-2.66%

-26.30%

Operating   Cash Flow

$316.47 Million

 $762.21 Million

  -$178.20 Million

Dividend   Yield

N/A

N/A

N/A

Short   Position

N/A

36.10%

N/A

 

Let's take a look at some more important numbers prior to forming an opinion on this stock.

E = Equity to Debt Ratio Is Normal  

The debt-to-equity ratio for SunPower is weaker than the industry average of 0.40, but it still qualifies as normal.

Debt-To-Equity

Cash

Long-Term Debt

SPWR

0.72

$506.60 Million

$676.43 Million

FSLR

0.16

$1.00 Billion

$563.04 Million

TSL

1.56

$807.28 Million

$1.37 Billion

 

T = Technicals Are Strong   

SunPower has been one of the hottest stocks throughout the broader market so far this year.

NEW! Discover a new stock idea each week for less than the cost of 1 trade. CLICK HERE for your Weekly Stock Cheat Sheets NOW!

1 Month

Year-To-Date

1 Year

3 Year

SPWR

61.21%

169.90%

169.00%

2.85%

FSLR

63.69%

40.27%

155.50%

-64.59%

TSL

36.41%

12.21%

-37.16%

-75.42%

 

At $15.18, SunPower is trading above all its averages.

50-Day   SMA

11.75

100-Day   SMA

9.81

200-Day   SMA

7.14

 

E = Earnings Have Been Weak            

Earnings have been unimpressive over the past two years. However, revenue has slowly but steadily improved.

2008

2009

2010

2011

2012

Revenue   ($)in   billions

1.44

1.52

2.22

2.37

2.42

Diluted   EPS ($)

1.05

0.35

1.75

-6.28

-3.01

 

When we look at the last quarter on a year-over-year basis, we see an increase in revenue and a decline in earnings.

3/2012

6/2012

9/2012

12/2012

3/2013

Revenue   ($)in   millions

494.13

595.90

648.95

678.52

635.43

Diluted   EPS ($)

-0.67

-0.71

-0.41

-1.22

-0.46

 

Now let's take a look at the next page for the Trends and Conclusion. Is this stock an OUTPERFORM, a WAIT AND SEE, or a STAY AWAY?

T = Trends Do Not Support the Industry

With a solar panel glut, decreased average selling prices, and substantial weakness in Europe, trends don't support the industry. However, it's no secret that solar should eventually succeed. It's just a matter of how eventual that will be.

NEW! Discover a new stock idea each week for less than the cost of 1 trade. CLICK HERE for your Weekly Stock Cheat Sheets NOW!

Conclusion

SunPower has enormous potential, and it's always good to be ahead of the curve, but there are substantial risks, especially considering that the stock market is at all-time highs, and the Bernake will eventually have to unwind monetary stimulus and raise in interest rates. When this occurs, there won't be a flight to solar stocks.

Sunday, August 25, 2013

Can JPMorgan Chase See Higher Prices?

With shares of JPMorgan Chase (NYSE:JPM) trading around $53, is JPM an OUTPERFORM, WAIT AND SEE or STAY AWAY? Let's analyze the stock with the relevant sections of our CHEAT SHEET investing framework:

T = Trends for a Stock’s Movement

JPMorgan Chase is a financial holding company that provides various financial services worldwide. The company is engaged in investment banking, financial services for consumers and small businesses, commercial banking, financial transaction processing, asset management, and private equity. Financial services companies like JPMorgan Chase are essential for well-functioning economies around the world.

Two former JPMorgan Chase have been criminally charged with covering up trading losses related to the London Whale fiasco. Federal prosecutors have charged the duo with falsifying books and records, conspiracy, fraud, and making false filings with the Securities and Exchange Commission. "This was not a tempest in a teapot, but rather a perfect storm of individual misconduct and inadequate internal controls," one prosecuting attorney said in an SEC filling.

As companies continue to operate and economies expand, leaders like JPMorgan Chase will provide valuable products and services to help financial transactions run as smoothly as possible. As one of the better big banks, JPMorgan Chase will lead the financial sector for many years.

T = Technicals on the Stock Chart Are Strong

JPMorgan Chase stock has seen a consistent uptrend in recent times. The stock is now trading at prices not seen for more than 10 years. Analyzing the price trend and its strength can be done using key simple moving averages. What are the key moving averages? The 50-day (pink), 100-day (blue), and 200-day (yellow) simple moving averages. As seen in the daily price chart below, JPMorgan Chase is trading slightly above its rising key averages, which signals neutral to bullish price action in the near term.

JPM

Source: Thinkorswim

Taking a look at the implied volatility and implied volatility skew levels of JPMorgan Chase options may help determine if investors are bullish, neutral, or bearish.

Implied Volatility (IV)

30-Day IV Percentile

90-Day IV Percentile

JPMorgan Chase Options

20.52%

33%

31%

What does this mean? This means that investors or traders are buying a small amount of call and put options contracts, as compared to the last 30 and 90 trading days.

Put IV Skew

Call IV Skew

September Options

Flat

Average

October Options

Flat

Average

As of Thursday, there is an average demand from call buyers or sellers and low demand by put buyers or high demand by put sellers, all neutral to bullish over the next two months. To summarize, investors are buying a small amount of call and put option contracts and are leaning neutral to bullish over the next two months.

E = Earnings Are Rising Quarter-Over-Quarter

Top 10 Heal Care Companies To Buy Right Now

Rising stock prices are often strongly correlated with rising earnings and revenue growth rates. Also, the last four quarterly earnings announcement reactions help gauge investor sentiment on JPMorgan Chase’s stock. What do the last four quarterly earnings and revenue growth (Y-O-Y) figures for JPMorgan Chase look like and more importantly, how did the markets like these numbers?

2013 Q2

2013 Q1

2012 Q4

2012 Q3

Earnings Growth (Y-O-Y)

32.23%

33.61%

54.89%

37.25%

Revenue Growth (Y-O-Y)

13.67%

-3.57%

10.16%

5.82%

Earnings Reaction

-0.30%

-0.60%

1.01%

-1.14%

JPMorgan Chase has seen rising earnings and revenue figures over the last four quarters. From these numbers, the markets have not been pleased with JPMorgan Chase’s recent earnings announcements.

P = Average Relative Performance Versus Peers and Sector

How has JPMorgan Chase stock done relative to its peers – Bank of America (NYSE:BAC), Citigroup (NYSE:C), and Wells Fargo (NYSE:WFC) — and sector?

JPMorgan Chase

Bank of America

Citigroup

Wells Fargo

Sector

Year-to-Date Return

21.18%

23.34%

28.54%

25.78%

24.84%

JPMorgan Chase has been an average relative performer, year to date.

Conclusion

JPMorgan Chase is a bellwether in the banking and financial space that forms an essential part of the United States financial system. Two former company’s traders have been criminally charged for covering up losses related to the London Whale incident. The stock has been rising higher in recent years and is now trading near prices not seen for more than 10 years. Over the last four quarters, earnings and revenue figures have been rising, however, investors in the company have not been pleased with JPMorgan Chase’s recent earnings announcements. Relative to its peers and sector, JPMorgan Chase has been an average year-to-date performer. Look for JPMorgan Chase to OUTPERFORM.

Friday, August 23, 2013

Tips to invest in equities

Choosing the right company

It is paramount for an investor to pinpoint the right company. This implies identifying a company which offers growth opportunities. Growth that is not just sustainable but also superior (that is, minimum 20 per cent) as well as profitable.

That is to say, the company should earn a superior return (of not less than 20 per cent) on its shareholders� capital (net worth).

Getting the investment 'time' perspective right

'Time is money' is a one-liner that says it all when it comes to equities! Timing your investment is extremely crucial. In terms of the investment 'time' perspective, in the short-run (typically 3 to 6 months), the performance of equity shares is driven more by market sentiment than by company fundamentals.So, you should invest so that you can participate in and benefit from the company's growth. Keeping this in mind, the ideal period to stay invested should preferably be greater than 5 years.

You would learn that in the long run, the relevance of the right price diminishes. If you choose the right company and have the right time perspective, in the longer term, it doesn't really matter too much whether you bought it at the lowest (right) price or not. This is because as long as the company is growing and you hold on to your investment, the Power of Compounding will multiply the value of your investment at a rate that will make the initial investment price insignificant. This makes a real mantra for wealth creation!

Returns you will earn

Taking the longer term perspective of staying invested for a period of 10 years and more, you can surely expect equities to yield returns ranging between 15 per cent and 20 per cent annually.

As unbelievable as it may sound, an overview of the performance of equities over two and a half decades confirms the same. For instance, had you invested in the Sensex for any one year period between 1979 and 2005, in 10 out of those 26 years, you would have lost money. But had you stayed invested for more than 10 years, your chances of loss would be almost zero. And that too, you would have made an average return of 17 to 18 per cent per annum.

Sunday, August 18, 2013

Weyerhaeuser Down to Neutral - Analyst Blog

Top 5 Oil Stocks To Invest In 2014

We recently downgraded Weyerhaeuser Company (WY) from Outperform to a Neutral recommendation, anticipating that the company will perform in line with the broader market.

Why the Downgrade?

Weyerhaeuser is a well renowned forest products company with a huge timberland asset. It serves a diverse clientele spread across the U.S., Canada, Japan, Europe, and other regions. The company currently provides a solid year-to-date return of 33%.

Over time, the company has solidified its timberland assets and is all set to further expand with the addition of Longview Timber LLC to its portfolio. The company's total ownership of the U.S. timberlands post the acquisition will likely reach 6.6 million acres.

Also, serious efforts are being made to improve operating efficiencies and reduce costs. To meet the end, non-performing assets are being disposed of to free resources for more productive use. Weyerhaeuser anticipates generating sequentially higher earnings from disposition of non-strategic timberlands in the second quarter. Of late, the company has initiated search for suitable alternatives for its homebuilding and real estate company, WRECO.

Apart from these, the recent increase of 18% in quarterly dividend rate points toward the company's healthy balance sheet and strong cash position. For 2013, management looks forward to better operating conditions as demand from major export destinations are expected to surge.

Despite all these positives, we have downgraded the recommendation on Weyerhaeuser to Neutral, presuming that these positives have already been discounted in the share price. This leaves little room for further expansion. Further, risks arising from stiff competition, exposure to currency translation and geopolitical issues cannot be completely ignored.

Other Stocks to Consider:

Weyerhaeuser currently ! has a market capitalization of $15.7 billion. Other stocks to watch out for in the industry are Louisiana-Pacific Corp. (LPX), Potlatch Corporation (PCH) and Rayonier Inc. (RYN).


Saturday, August 17, 2013

Health Insurance Stock Outlook - July 2013 - Industry ...

The health insurance industry has confronted many external challenges in the recent past such as federal, state legislative and regulatory reforms; a challenge to meet the demand of more price- and service-conscious consumers, a fiercely competitive market, shift of customer mix and uncertain economic conditions in the U.S. and abroad, just to name a few.

Notwithstanding the headwinds, the industry is "thriving under stress." Most of the top players -- including CIGNA Corp. (CI), WellPoint Inc.
(WLP), Aetna Inc. (AET), Humana Inc. (HUM), Molina Healthcare (MOH) and Health Net, Inc. (HNT) -- reported ahead of the Zacks Consensus estimates in 2013 Q1, while UnitedHealth Group Inc. (UNH) reported in line. The earnings outperformance was driven by lower medical inflationary trends and strong operating performance.

Following the first quarter results, most of the carriers raised their 2013 earnings estimates, reflecting optimism for the rest of the year. We, however, expect narrower margins in 2013 compared to the strong margins in the 2010-2012 period, when favorable prior-period claim development and continued lower-than-expected utilization helped the industry witness strong margins.

Margins are anticipated to decline in 2013 and beyond as medical costs will likely return to more normal levels and pricing may not increase to that extent.

About the Industry

The health and medical insurance industry is an integral part of the U.S. economy. According to the Centers for Medicare and Medicaid Services, U.S. health expenditures account for approximately 18% of the country's GDP. According to the World Health Organization, health care expenditure per person in the U.S. is the highest in the world.

Despite a huge sum of money being spent on health care, millions of Americans lack health insurance coverage or are underinsured. This is largely due to a dysfunctional health care system, in place for decades. To rein in wastage and make health care more accessible, ef! fective and affordable, the current administration came out with a major reform in the shape of the Affordable Care Act, commonly referred to as Obamacare. This massive piece of legislation has elicited mixed responses from the get-go, largely along partisan lines, and is still not fully functional.

Industry Ranking

Within the Zacks Industry classification, Health Insurance is broadly grouped into two sectors: Medical and Finance. The Medical HMO industry is within the Medical sector while the Multi-line Insurance industry is within the Finance sector. The Multi-line insurance industry houses within its category all kinds of operators that have multiple lines of insurance business, including healthcare.

We rank all the industries in the 16 Zacks sectors based on the earnings outlook for the constituent companies in each industry. The ranking is available on the Zacks Industry Rank page. http://www.zacks.com/stocks/industry-rank

As a point of reference, the outlook for industries with Zacks Industry Rank #88 and lower is 'Positive,' between #89 and #176 is 'Neutral' and
#177 and higher is 'Negative.' The current Zacks Industry Rank for the Medical HMO industry is #18, down 8 spots in the last week, while the Multi-line Insurance industry is currently ranked #17, up 10 spots over the past week. With both these industries located towards top of the Zacks Industry Rank list, the outlook for the healthcare insurance space remains positive.

Please note that the Zacks Rank for stocks, which is at the core of our Industry Outlook, has an impressive track record, verified by outside auditors, to foretell stock prices, particularly over the short term (1 to 3 months). The rank, along with Expected Surprise Prediction (ESP) (Read:
Zacks Earnings ESP: A Better Way to Find Earnings Surprises) helps in predicting the probability of earnings surprises.

Earnings Trends

The broader Finance sector, of which Health Insurance is a part, remains in excellent shap! e. The fi! rst quarter 2013 results for the sector were impressive in terms of both beat ratios (percentage of companies coming out with positive surprises) and growth.

The earnings "beat ratio" was 73.4% while the revenue "beat ratio" was 51.9%. Total earnings for this sector were up 7.7%, slightly moderating from the 10.0% growth in the fourth quarter of 2012. Total revenues moved north 5.5% in the quarter versus 23.1% in the prior quarter.

Looking at the consensus earnings expectations for the rest of the year, we remain encouraged since earnings are expected to grow 19.1% in the second quarter, 7.6% in the third quarter and 27.6% in the fourth quarter, thereby registering full-year 2013 growth of 14.0%.

Health Care Overhaul

The Patient Protection and Affordable Care Act (PPACA) was passed in 2010 and marked the beginning of a multiyear implementation process. It is the most substantial overhaul in the history of the nation's health care sector.

The reform was intended to provide coverage to the 32 million uninsured Americans, to make health care facilities more affordable, expand coverage for customers with pre-existing health conditions and keep a check on health insurers.

Certain significant provisions of the legislation were: mandated coverage requirements; rebates to policyholders based on minimum benefit ratios, adjustments to Medicare Advantage premiums, the establishment of state-based exchanges, greater investment in health IT; annual insurance industry premium-based assessment, reduction in federal assistance on Medicare Advantage, and restriction on rescission of policies and elimination of annual as well as life time maximum limits.

The Reform has been on a rough patch since its inception, with opponents challenging its individual mandate and Medicaid expansion clause and dragging it to court. Insurers lobbied against most of its provisions and opposition parties swore to repeal the whole law if they were elected. But the law survived the challe! nges with! the Supreme Court upholding the constitutionality of its individual mandate -- the core of the reform.

Also, the re-election of Barack Obama for a second term provides the necessary ratification to the health care reform. That said, the full implementation of the reform is far from guaranteed, given the substantial leeway states enjoy in enforcing key parts of the legislation, particularly the setting up of exchanges and expansion of Medicaid.

The Changing Face of Health Insurance Industry

Obama's re-election has made it certain that his signature Health Care law is here to stay, putting behind the prevailing ambiguity. Obama's second term will see implementation of key provisions across the industry. However, the main issue in the short- to mid-term is the uncertainty over how the regulatory reform will play out.

So far, the carriers have handled the impact of implementation of some of the less onerous provisions of the reform (relating to MLR requirements, a ban on denial of coverage due to pre-existing ailment, dependent coverage up to the age of 26, annual rate review) relatively well.

For the moment, however, the biggest question is how the most impactful provisions of the law (relating to setting up of insurance exchanges, individual mandate, ICD-10 requirements, pre-existing conditions, Medicaid expansion, an annual insurance industry assessment of $8 billion in 2014 with increasing annual amounts thereafter), which are due to be implemented in 2014, will affect the industry. Investor sentiment toward the reform implementation in 2014 and beyond will be the driving factor for managed care stocks.

Exchanges will act as an online marketplace where consumers who are under-insured or uninsured will be able to shop for subsidized coverage and small businesses can buy more affordable plans for their workers. A key risk to insurers is that insurance exchanges will lead to commoditization of insurance products, making product offerings highly standardized. ! This prod! uct standardization along with a framework for strong government price regulation will expectedly lead to low profit margins for the carriers in the long run.

While the individual mandate provision will bring into loop approximately 32 million uninsured people, the gain in revenues due to increasing industry enrollment is expected to be offset to a large extent by the costs to realign their business to comply with the new rules (ICD-10 coding) and deal with other challenges.

Several provisions in the Health Reform -- excise tax on medical devices, annual fees on prescription drug manufacturers, enhanced coverage requirements and the prohibition of pre-existing condition exclusions -- will likely increase insurers medical costs.

Moreover, the annual insurance industry assessment ($8 billion to be levied on the insurance industry in 2014, increasing to $14.3 billion by
2018, with increasing annual amounts thereafter), which is not deductible for income tax purposes, and the temporary reinsurer fee ($25 billion to be levied on all commercial lines of business including insured and self-funded arrangements, over a three-year period starting in 2014), will increase insurer operating costs.

In the meantime, rules of the road remain uncertain as the recent delay business mandate provision of the legislation shows. Insurers do not know what exactly will be expected of them, what changes they will be forced to implement, or what expenses they might have to incur to meet new data and regulatory demands. Carriers may see potentially game-changing developments threatening their ability to achieve top- and bottom-line growth. However, insurers are being proactive, trying very hard not just to survive but to prosper.

Aiming for Global Markets

With organic growth remaining challenged, carriers in the health insurance sector are flocking toward the international markets, which specifically appear attractive on account of lesser regulations, higher margins and lower com! petition.! Additionally, pressure on social health care systems along with increasing wealth and education in emerging markets are leading to higher demands for health insurance and financial security. This provides carriers with a vast market opportunity.

Companies like Cigna and Aetna, which have active presence overseas, believe that their international business is a positive differentiator and a key driver of higher-than-peer growth rates. Both companies are targeting to penetrate deeper mainly in the emerging economies of Asia and the Middle East.

UnitedHealth is another instance. The company already has a presence in Australia, the Middle East and UK. In Oct 2012, it expanded its portfolio with the purchase of a controlling stake in AmilParticipacoes, Brazil's biggest health insurer and hospital operator, for $4.9 billion. The deal will give it access to a fast-growing market bolstered by a rising middle class.

This acquisition attests the fact that insurers are desperately seeking to graze international pastures. The company already has a significant presence in Portugal, India and the Middle East through joint ventures.

Though the U.S. health insurance industry currently has little international presence, insurers are fast catching up. We expect to see more international deals going forward.

Health Insurers Investing in Technology

There has been unprecedented spending on health information technology (HIT). HIT includes electronic health records (EHRs), health information exchanges (HIEs) and other initiatives.

Health IT, which helps providers communicate better with each other about patient care, reduces medical errors, paperwork and needless duplicate screenings and tests, leads to better coordinated patient care and lower health care costs. These have increased current health care information technology spending. Financial incentives offered by regulators to providers and hospitals for the meaningful use of health care IT products are primarily dri! ving huge! IT spending.

From 2013, all hospitals serving Medicare patients with the most common conditions will be paid for the quality of the care they provide in addition to the quantity of services offered. Some of the companies are also sharing data. We expect the trend will continue to grow as pay-for-performance takes root.

Reimbursement Cuts to the Medicare Advantage Program

Medicare Advantage plans are privately run versions of the federally funded Medicare program for the elderly and disabled. Last month, the U.S.
Centers for Medicare& Medicaid Services proposed to reduce reimbursement payments by 3.5% every year during 2014 to 2017.The proposed reduction in rates comes in addition to the 2% reduction in reimbursement rates related to mandatory cuts to U.S. government spending -- known as sequestration -- that went into effect earlier this year. This has left the insurers worried since this could translate into big payments cuts.

Medicare Advantage plans are also challenged by the health care overhaul and the steep federal budget cuts. Insurers' profits also are expected to be pressured by the growing cost of care and a premium tax imposed to help fund the overhaul.

Medicare Advantage Remains a Preferred Market

Despite reimbursement cuts to Medicare Advantage, insurers remain attracted to this line of business as they expect to make up the lost revenues from the ever-increasing number of seniors opting for the Medicare Advantage program. Enrollment in such plans is expected to increase in 2013.

According to U.S. Census data, the population of Medicare beneficiaries will grow by 36% by the end of this decade led by a vast aging baby boomer population. Until recently, only two of the public providers -- UnitedHealth and Humana -- were the primary market share holders. However, consolidation in the market has led to a scramble for market share.

Carriers in the health insurance sector are in a race to win Medicare Advantage market share a! nd the fa! stest way of achieving the target is to acquire a company in the same business. This is evident from instances like Cigna's acquisition of HealthSpring Inc. UnitedHealth's acquisition of XLHealth Corp. Aetna's acquisition of Coventry Health Care Inc. and WellPoint's acquisition of Amerigroup Inc.

Consolidation Continues

Notwithstanding the fact that the health insurance industry has been witnessing copious mergers and acquisitions for the last several years, the landscape created by the Health Care Reform has set the stage right for further consolidation. In the changed environment, small insurers are becoming inefficient. The inability to achieve the required scale to be profitable is forcing these small players to get acquired.

OPPORTUNITIES

Over the next few years, growth opportunities for the players in the health insurance sector will be driven by:

Health expenditure and reliance on managed care are gradually increasing. Centers for Medicare and Medicaid Services total health care spending is projected to grow from an estimated $2.8 trillion last year to $4.8 trillion by 2021, an increase of 70%. This clearly points to the fact that the health care industry will most certainly outstrip broader economic growth. Moreover, over the same time frame, managed care penetration is expected to grow to about 50% of the total national health care spending, up from approximately 33% at present, driven by increased reliance on insurers in managing government's fee-for-service Medicare and Medicaid products. Recent Census figures show that seniors constitute a larger share of American population than ever before. The trend will only gain steam in the years ahead. Consequently, the aging population is expected to drive industry demand as they would aim to reduce their health-related costs. We expect most of the companies within our coverage to benefit from the trend. Among others, Molina Healthcare with a Zacks Rank #1 (Strong Buy), and Aetna, Cigna, UnitedHealth Group! and Well! Point with a Zacks Rank #2 (Buy), and Humana witha Zacks Rank #3 (Hold) will offer good investment opportunities going forward.
Let's have a quick look at some of these companies:

Cigna (CI) remains attractive given its strong growth profile, significant presence in Medicare Advantage and a growing commercial self insured business. Its International segment has also been growing at a double digit rate.

The company has been delivering solid earnings and the trend is expected to continue. We are more optimistic about the company now that it has shed its exposure to its run off portfolio, which had traditionally been imparting volatility to its earnings.

Aetna (AET) has also been performing well over the past several quarters. The company is making strong progress in its Medicare business. It is also growing its international business for diversification benefits. A solid balance sheet, well-controlled debt and adequate liquidity provide overall strength.

UnitedHealth (UNH) has also been performing well for the past many quarters. We are optimistic that it will outperform in a rapidly changing industry environment, given its industry-best execution and management, product positioning, scale, and technology. Contrary to earlier conjectures, the company has limited exposure to the downside risks associated with the health reform.

WEAKNESSES

Though none of the health insurance stocks under our coverage hold a Zacks Rank #5 (Strong Sell) or even a Zacks Rank #4 (Sell), we expect the following factors to negatively impact the industry:

Health insurers are expected to face challenges related to medical-cost inflation. The Centers of Medicare and Medicaid Services expects U.S. health expenditure to increase at an average annual rate of 5.7% to $3.3 trillion during the next five years. Furthermore, the demand for Medicare is expected to increase as the baby-boomer generation goes into retirement. Consequently, insurers will likely face increased pressure! to maint! ain medical-benefit ratios due to the lack of funds for these programs along with government's initiatives to control costs. The U.S. economy continues to experience a period of slow growth and high unemployment. Workforce reductions have caused corresponding membership losses in insurance companies' fully-insured commercial group business. Continued weakness in the U.S. economy and high unemployment rate will adversely affect medical membership, operations, financial position and cash flows.
The overall thrust of healthcare reform and regulatory changes will certainly change the face of the industry in the long run.

Friday, August 16, 2013

Will Wolverine's 2Q Earnings Beat? - Analyst Blog

Wolverine World Wide Inc. (WWW) is slated to report its second-quarter fiscal 2013 results on Jul 9, 2013. In the last quarter, it posted a positive surprise of 50%. Let's see how things are shaping up for this announcement.

Growth Factors this Past Quarter

Benefiting largely from the acquisition of PLG group, Wolverine posted strong first-quarter 2013 results. On account of the growth in the top line, the company's gross profit nearly doubled, while adjusted operating profit rose 78.6% year over year.

Earnings Whispers?

Our proven model does not conclusively show that Wolverine is likely to beat earnings this quarter. That is because a stock needs to have both a positive Earnings ESP (Read: Zacks Earnings ESP: A Better Method) and a Zacks Rank #1, #2 or #3 for this to happen. This is not the case here as you will see below.

Zacks ESP: ESP for Wolverine is 0.00%. This is because the Most Accurate Estimate stands at 34 cents, in line with the Zacks Consensus Estimate.

Zacks Rank #2 (Buy): Wolverine's Zacks Rank #2 (Buy) lowers the predictive power of ESP because the Zacks Rank #2 when combined with a 0.00% ESP makes surprise prediction difficult. We caution against stocks with Zacks Ranks #4 and #5 (Sell rated stocks) going into the earnings announcement, especially when the company is seeing negative estimate revisions momentum.

Other Stocks to Consider

Here are some other companies you may want to consider as our model shows they have the right combination of elements to post an earnings beat this quarter:

ManpowerGroup Inc. (MAN), Earnings ESP of +3.33% and a Zacks Rank #1 (Strong Buy).

Deckers Outdoor Corp. (DECK), Earnings ESP of +13.21% and a Zacks Rank #2 (Buy).

Rent-A-Center, Inc. (RCII), Earnings ESP of +1.33% and a Zacks Rank #3 (Hold).

Thursday, August 15, 2013

Back to Basics: Valuation Ratios That Are Important to Value Investors

Top 10 Undervalued Companies To Invest In 2014

GuruFocus will display valuation ratios such as P/E ratio, P/S ratio, P/FreeCashFlow, Shiller P/E and P/B on its new stock summary page. This is in addition to the intrinsic values GuruFocus will display. These are the explanations of each ratio.

P/E Ratio

The P/E ratio is the most widely used ratio in the valuation of stocks. It is calculated as:

P/E Ratio = Share Price / Earnings per share (EPS)

It can also be calculated from the numbers for the whole company:

P/E Ratio = Market Cap / Net Income

There are at least three kinds of P/E ratios used by different investors. They are Trailing Twelve Month P/E Ratio or P/E (ttm), forward P/E, or P/E (NRI). A new P/E ratio based on inflation-adjusted normalized P/E ratio is called Shiller P/E, after Yale professor Robert Shiller.

In the calculation of P/E (ttm), the earnings per share used are the earnings per share over the past 12 months. For Forward P/E, the earnings are the expected earnings for the next twelve months. In the case of P/E (NRI), the reported earnings less the non-recurring items are used.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, Shiller P/E is also called PE10.

Guru Explains:

The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the P/E ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn b! ack the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower-P/E stocks are more attractive than higher P/E stocks. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG. PEG is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.

Because the P/E ratio measures how long it takes to earn back the price you pay, the P/E ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the Price/Sales ratio and Price/Cash Flow or Price/Free Cash Flow, the P/E ratio measures the valuation based on the earning power of the company. This is where it is different from the Price/Book ratio, which measures the valuation based on the company's balance sheet.

Be Aware:

Investors need to be aware that the P/E ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and P/E ratios are artificially low. It is usually a bad idea to buy a cyclical business when the P/E is low. A better ratio to identify the time to buy a cyclical businesses is the Price-to-Sales Ratio (P/S).

Price-to-Sales Ratio (P/S)

The P/S Ratio is another ratio widely used to value stocks. It was first used by Ken Fisher. It is calculated as:

P/S Ratio = Share Price / Revenue per Share

It can also be calcu! lated fro! m the numbers for the whole company:

P/S Ratio = Market Cap / Total Revenue

The revenue here is for the trailing 12 months.

Guru Explains:

The P/S ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The P/S ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The P/S ratio is a great valuation tool for evaluating cyclical businesses where the P/E ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the P/S ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the Price/Earnings ratio and Price/Cash Flow or Price/Free Cash Flow, the P/E ratio measures the valuation based on the earning power of the company. This is where it is different from Price/Book ratio, which measures the valuation based on the company's balance sheet.

Be Aware:

The P/S ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.

Price to Book Ratio (pb)

The price-to-book ratio, or P/B ratio, can be calculated as follows:

P/B Ratio = Share Price / Book Value per Share

It can also be calculated from the numbers for the whole company:

P/B Ratio = Market Cap / Total Equity

A closely related ratio is ca! lled Pric! e-to-Tangible-Book Ratio. The difference between Price-to-Tangible-Book Ratio and Price-to-Book Ratio is that book value other than intangibles are used in the calculation.

Guru Explains:

Unlike valuation ratios relative to the earning power such as P/E ratio, P/S ratio or Price-to-Free-Cash-Flow ratio, the Price-to-Book Ratio measures the valuation of the stock relative to the underlying asset of the company.

The Price-to-Book Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.

Be Aware:

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio can not be applied to them.

Related: P/E ratio, P/S ratio, Shiller P/E or Price-to-Free-Cash-Flow ratio, Book Value, Tangible Book Value

Price-to-Free-Cash-Flow ratio

Price-to-Free-Cash-Flow ratio is calculated as follows:

Price-to-Free-Cash-Flow = Share Price / Free Cash Flow per Share

Or

Price-to-Free-Cash-Flow = Market Cap / Total Free Cash Flow.

Free Cash Flow is calculated as:

Free Cash Flow per Share

= Cash Flow from Operations + (Increase) Decrease in Prop, Plant & Equipment

= Net Income + Depreciation & Amortization (DDA) – Change in Net Working Capital – Capital Expenditure.

Guru Explains:

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.

Be Aware:

In real business, Free Cash Flow can be affected by the change in accounts! receivab! le, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.

Related: : P/E ratio, P/S ratio, Shiller P/E or Price-to-Free-Cash-Flow ratio, Book Value, Free Cash Flow, DCF Calculator

Shiller P/E Ratio

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Guru Explains:

Compared with the regular P/E ratio, which works poorly for cyclical businesses, the Shiller P/E smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller P/E should give similar results to regular P/E.

Compared with the P/S ratio, the Shiller P/E makes the comparison between different industries more meaningful.

Be Aware:

The Shiller P/E assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, the Shiller P/E and P/S ratio will give false valuations.

Related: P/E ratio, P/S ratio

We welcome your feedback. In the meantime, please also read How to calculate the intrinsic value of a stock.

If you are not a Premium Member, we invite you for a 7-Day Free Trial.

Monday, August 12, 2013

5 Best Medical Stocks To Invest In Right Now

Organovo Holdings (NYSEMKT: ONVO  ) was one of last week's biggest winners, soaring 55% after making the leap to the more prolific NYSE MKT exchange.

A bigger stage plays well when you have a neat tale to tell, and Organovo certainly has all of the makings of a hot story stock.

Organovo takes 3-D printing to a seemingly implausible extreme. Its bioprinting process can generate a reasonable proxy to human tissue in a lab that can be used in culture plates or bioreactors for medical research and therapeutic applications.

Yes, that's pretty cool, and recent investors seeing the stock jump from $3.87 to $6.01 in a single week have a good reason to get giddy.

Unfortunately, long-term investors have seen this before.

The stock traded as low as $2.35 in May of last year, only to peak at $10.90 a month later and bottom out at $1.49 the month after that.

5 Best Medical Stocks To Invest In Right Now: Compugen Ltd.(CGEN)

Compugen Ltd. operates as a drug and diagnostic discovery company based on computer-based discovery capabilities to predict and select novel product candidates. Through in silico prediction and selection, the resulting novel molecules are synthesized and validated utilizing traditional in vitro and in vivo experimental procedures. The company provides these validated product candidates to pharmaceutical, biotech, and diagnostic companies under licensing and other commercialization arrangements. Its research and discovery efforts are focused primarily on therapeutic proteins and peptides, and monoclonal antibodies, and primarily in the fields of immunology and oncology. Its therapeutic peptide and protein related platforms include Protein Family Members Discovery Platform, Protein-Protein Interaction Blockers, GPCR Therapeutic Peptide Ligands, Disease-Associated Conformation Blockers, Intracellular Drug Delivery, Viral Peptides, and Splice Variant based Therapeutic Proteins . The company?s monoclonal antibody related platforms comprise Monoclonal Antibody Targets. Its other therapeutic and diagnostic platforms consist of Nucleic-Acid Disease Markers, Protein Disease Markers, Nucleic-Acid Preclinical Toxicity Markers, Non-SNP Drug Response Markers, and New Indications. Its therapeutic peptide and protein product candidates comprise CGEN-15001, a novel protein for the treatment of autoimmune disorders; CGEN-25017, a novel peptide antagonist of the Angiopoietin/Tie-2 pathway; CGEN-855, a peptide agonist of the FPRL1 GPCR receptor; CGEN-856 and CGEN-857, which are MAS GPCR peptide agonists; CGEN-25007, an antagonist of the gp96 protein; and CGEN-25009, a peptide of the LGR7 receptor. The company also offers monoclonal antibody target product candidates, including CGEN-671, a drug for multiple epithelial tumors; CGEN-928, a drug for multiple myeloma; and CGEN-15001T, a novel B7/CD28 family member. Compugen Ltd. was founded in 1993 and is based in Te l Aviv, Israel.

Advisors' Opinion:
  • [By Michael Shulman]

    Compugen Ltd. (NASDAQ: CGEN) is the world’s leading molecular intellectual property company. Based in Israel, the company has revolutionized the early phases of drug development through a highly automated process of exploring and selecting molecules with the greatest promise to serve as the basis for a particular treatment.

    The company licenses its peptides and proteins for a fee to the who’s who of the drug industry, and also receives a back-end cut of any drug that makes it to market using its discoveries.

    Compugen just announced that it entered into an agreement with Baize Investments under which it will receive $5 million in R&D funding. My target for CGEN is $20 in three to five years.

5 Best Medical Stocks To Invest In Right Now: Impax Laboratories Inc.(IPXL)

Impax Laboratories, Inc., a specialty pharmaceutical company, engages in the development, manufacture, and marketing of bioequivalent pharmaceutical products. The company operates in two divisions, Global Pharmaceuticals and Impax Pharmaceuticals. The Global Pharmaceuticals division develops, manufactures, sells, and distributes generic pharmaceutical products. It provides its generic pharmaceutical prescription products directly to wholesalers and retail drug chains; and generic pharmaceutical over-the-counter and prescription products through unrelated third-party pharmaceutical entities. The Impax Pharmaceutical division develops proprietary brand pharmaceutical products that address central nervous system disorders, including Alzheimer?s disease, attention deficit hyperactivity disorder, depression, epilepsy, migraines, multiple sclerosis, Parkinson?s disease, and schizophrenia, as well as promotes third-party branded pharmaceutical products. As of May 2, 2011, the com pany marketed 101 generic pharmaceuticals, which represent dosage variations of 29 different pharmaceutical compounds; and another 16 of its generic pharmaceuticals representing dosage variations of 4 different pharmaceutical compounds. It markets and sells its generic pharmaceutical prescription drug products in the continental United States and the Commonwealth of Puerto Rico. The company has a strategic alliance agreement with Teva Pharmaceuticals Curacao N.V. Impax Laboratories, Inc. was founded in 1993 and is headquartered in Hayward, California.

Advisors' Opinion:
  • [By Michael Shulman]

    The not-so-small generic drug maker Impax Laboratories (NASDAQ: IPXL) has arguably the best manufacturing technology for time-released drugs in the entire generic industry.

    Pfizer’s (NYSE: PFE) patent for its $11 billion cholesterol drug Lipitor expires this year, and we know IPXL believes it has the expertise to manufacture a sophisticated statin such as Lipitor given recent legal actions concerning Merck’s drug Vytorin, a combination of a competing statin and a blood pressure drug. In other words, IPXL has the technical expertise to enter this market should it choose to do so.

    Two other major product introductions are anticipated in 2011 — generic Concerta for ADHD and generic Solodyn for bacterial infections, currently with combined sales of $1.8 billion.

    My target for the stock is $35-$40 in one to two years. IPXL is also the possible target of an acquirer.

10 Best Low Price Stocks To Own For 2014: Scancell Holdings PLC (SCLP.L)

Scancell Holdings PLC is a United Kingdom-based company. The Company�� principal activity of the consists of the discovery and development of monoclonal antibodies and vaccines for the treatment of cancer. In April 2012, the Company completed recruitment to the Phase 1 clinical trial of SCIBI. In May 2012, the Company commenced recruitment and treatment of the first patient in the second part of it Phase 1/2 clinical trial of SCIBI. The Phase 2 part of the trial is conducted in five United Kingdom centers in Nottingham, Manchester, Newcastle, Leeds, and Southampton. On August 15, 2012, the Company announced the development of a platform technology, Moditope.

5 Best Medical Stocks To Invest In Right Now: StemCells Inc (STEM.W)

StemCells, Inc. (StemCells), incorporated in August 1988, is engaged in the research, development, and commercialization of stem cell therapeutics and related tools and technologies for academia and industry. The Company is focused on developing and commercializing stem and progenitor cells as the basis for therapeutics and therapies, and cells and related tools and technologies to enable stem cell-based research and drug discovery and development. The Company�� primary research and development efforts are focused on identifying and developing stem and progenitor cells as potential therapeutic agents. The Company has two therapeutic product development programs, including its CNS Program, which is developing applications for HuCNS-SC cells, its human neural stem cell product candidate, and its Liver Program, which is characterizing the Company�� human liver cells as a therapeutic product.

CNS Program

The Company in its CNS Program, is in clinical development with its HuCNS-SC cells for a range of disorders of the central nervous system. The CNS includes the brain, spinal cord and eye. In February 2012, the Company had completed a Phase I clinical trial in Pelizeaus-Merzbacher Disease (PMD), a fatal myelination disorder in the brain.

The Company�� CNS Program is focused on developing clinical applications, in which transplanting HuCNS-SC cells protect or restore organ function of the patient before such function is irreversibly damaged or lost due to disease progression. The Company�� initial target indications are PMD, and more generally, diseases in which deficient myelination plays a central role, such as cerebral palsy or multiple sclerosis; spinal cord injury, disorders in which retinal degeneration plays a central role, such as age-related macular degeneration or retinitis pigmentosa. The Company�� product candidate, HuCNS-SC cells, is a purified and expanded composition of normal hum an neural stem cells. Its HuCNS-SC cells can be directly tr! a! nsplanted.

Liver Program

Liver stem or progenitor cells offer an alternative treatment for liver diseases. A liver cellular therapy or cell-based therapeutic provide or support liver function in patients with liver disease. The Company held a portfolio of issued and allowed patents in the liver field, which cover the isolation and use of both hLEC cells and the isolated subset, as well as the composition of the cells themselves.

The Company�� range of cell culture products, which are sold under the SC Proven brand, includes iSTEM, GS1-R, GS2-M, RHB-A, RHB-Basal, NDiff N2, and NDiff N2B27. Its iSTEM is a serum-free, feeder-free medium that maintains mouse embryonic stem cells in their pluripotent ground state by using selective small molecule inhibitors to block the pathways, which induce differentiation. RHB-A is a defined, serum-free culture medium for the selective culture of human and mouse neural stem cells and their maintenanc e and expansion as adherent cell populations. RHB-Basal is a defined, serum-free basal medium. When supplemented with specific growth factors, this media is formulated for the propagation and differentiation of adherent neural stem cells. RHB-Basal can also be tailored to specific-cell type requirements by the addition of customer preferred supplements.

The Company�� NDiff N2 is a defined serum-free scell culture supplement for the derivation, maintenance, expansion and/or differentiation of human and mouse embryonic stem (ES) cells and tissue-derived neural stem cells supplement. Its NDiff N2-AF is a serum-free and animal component-free version of NDiff N2. Its NDiff N2B27 is a defined, serum-free medium for the differentiation of mouse embryonic stem cells to neural cell types. NDiff N27-AF is a serum-free and animal component-free version of NDiff N27. Its GS1-R is a serum-free media formulation shown to enable the derivation and long-term maintenance of tr ue, germline competent rat embryonic stem cells without! the ! ad! dition ! of cytokines or growth factors. Its GS2-M is a defined, serum- and feeder-free medium for the derivation and long-term maintenance of true, germline competent mouse iPS cells.

The Company also markets a number of antibody reagents for use in cell detection, isolation and characterization. These reagents are also under the SC Proven brand and it includes STEM24, STEM101, STEM121 and STEM123. Its STEM24 is a human antibody that recognizes human CD24, also known as heat stable antigen (HSA), a glycoprotein expressed on the surface of many human cell types, including immature human hematopoietic cells, peripheral blood lymphocytes, erythrocytes and many human carcinomas. Its CD24 is also a marker of human neural differentiation. Its STEM101 is a human-specific mouse antibody that recognizes the Ku80 protein found in human nuclei. Its STEM121 is a human-specific mouse antibody that recognizes a cytoplasmic protein of human cells. Its STEM123 is a human-specific mouse antibody that recognizes human glial fibrillary acidic protein (GFAP).

The Company�� Other products marketed under SC Proven include total cell genomic DNA (gDNA), RNA and protein lysate reagents purified from homogenous stem cell populations for intra-comparative studies, such as Epigenetic fingerprinting, Southern, Western and Northern blots, PCR, RT-PCR and microarrays. This range of purified stem cell line lysates includes mouse embryonic stem (ES) cells propagated in SC Proven 2i inhibitor-based GS2-M media and mouse ES cell-derived and fetal tissue-derived neural stem (NS) cells propagated in SC Proven RHB-A media.

5 Best Medical Stocks To Invest In Right Now: Navidea Biopharmaceuticals Inc (NAVB)

Navidea Biopharmaceuticals, Inc. (Navidea), formerly Neoprobe Corporation, incorporated in 1983, is a biopharmaceutical company focused on the development and commercialization of precision diagnostic agents. As of December 31, 2011, the Company�� radiopharmaceutical development programs included Lymphoseek (Lymphoseek, Kit for the Preparation of Technetium Tc99m for Injection), a radiopharmaceutical agent for lymph node mapping; AZD4694, an imaging agent, and RIGScan, a tumor antigen-specific targeting agent. In January 2012, the Company executed an option agreement with Alseres Pharmaceuticals, Inc. (Alseres) to license [123I]-E-IACFT Injection, also called Altropane, an Iodine-123 radiolabeled imaging agent, being developed as an aid in the diagnosis of Parkinson�� disease, movement disorders and dementia. In August 2011, the Company sold its gamma detection device line of business (the GDS Business) to Devicor Medical Products, Inc.

Lymphoseek

Navidea�� pipeline includes clinical-stage radiopharmaceutical agents used to identify the presence and status of disease. Lymphoseek (Kit for the Preparation of Technetium Tc99m for Injection) is a lymph node targeting agent intended for use in intraoperative lymphatic mapping (ILM) procedures and lymphoscintigraphy employed in the overall diagnostic assessment of certain solid tumor cancers. The lymph system is a component of the body�� immune system. The key components of the lymph system are lymph nodes-small anatomic structures that contain disease-fighting lymphocytes, filter lymph of bacteria and cancer cells, and signal infection in response to heightened levels of pathogens. In Navidea�� Phase III clinical studies of Lymphoseek, it detected over 99% of positive nodes identified by vital blue dye (VBD). As of December 31, 2011, Navidea, in co-operation with UC, San Diego affiliate (UCSD), completed or initiated five Phase I clinical trials, one multi-center Phase II trial and three multi-center Phase II trials inv! olving Lymphoseek. Two Phase III studies were completed in subjects with breast cancer and melanoma. During the year ended December 31, 2011, data from NEO3-09 were released, which indicated that all primary and secondary endpoints for the study were met. As of December 31, 2011, third Phase III clinical trial for Lymphoseek in subjects with head and neck squamous cell carcinoma (NEO3-06) was in progress.

AZD4694

AZD4694 is a Fluorine-18 labeled precision radiopharmaceutical candidate for use in the imaging and evaluation of patients with signs or symptoms of cognitive impairment such as Alzheimer's disease (AD). It binds to beta-amyloid deposits in the brain that can then be imaged in positron emission tomography (PET) scans. Amyloid plaque pathology is a required feature of AD and the presence of amyloid pathology is a supportive feature for diagnosis of probable AD. Patients who are negative for amyloid pathology do not have AD. AZD4694 has been studied in several clinical trials. Clinical studies through Phase IIa have included more than 80 patients to date, both suspected AD patients and healthy volunteers. No significant adverse events have been observed. Results suggest that AZD4694 has the ability to image patients quickly and safely with high sensitivity.

RadioImmunoGuided Surgery

As of December 31, 2011, RIGScan had been studied in a number of clinical trials, including Phase III studies. Navidea has conducted two Phase III studies, NEO2-13 and NEO2-14, of RIGScan in patients with primary and metastatic colorectal cancer, respectively. Both studies were multi-institutional involving cancer treatment institutions in the United States, Israel, and the European Union.

The Company competes with Pharmalucence, Eli Lilly, Bayer Schering, General Electric and GE Healthcare.

Saturday, August 10, 2013

Exxon Mobil: Are All-Time Highs Imminent?

With shares of Exxon Mobil (NYSE:XOM) trading around $89, is XOM an OUTPERFORM, WAIT AND SEE or STAY AWAY? Let's analyze the stock with the relevant sections of our CHEAT SHEET investing framework:

T = Trends for a Stock’s Movement

Exxon Mobil is a manufacturer and marketer of commodity petrochemicals, including olefins, aromatics, polyethylene and polypropylene plastics, and a range of specialty products. The company has a number of divisions and affiliates with names that include ExxonMobil, Exxon, Esso or Mobil that operate or market products in the United States and other countries of the world. Exxon Mobil's principal business is energy, involving exploration for and production of crude oil and natural gas; manufacture of petroleum products; and transportation and sale of crude oil, natural gas, and petroleum products. Energy is essential to global growth and day-to-day operations of companies and consumers worldwide. So long as crude oil is a main source of energy, a bellwether like Exxon Mobil will continue to see rising profits well into the future.

T = Technicals on the Stock Chart are Strong

Exxon Mobil stock has seen a consistent uptrend extending back several years. The stock is now consolidating slightly below all-time high prices. Analyzing the price trend and its strength can be done using key simple moving averages. What are the key moving averages? The 50-day (pink), 100-day (blue), and 200-day (yellow) simple moving averages. As seen in the daily price chart below, Exxon Mobil is trading slightly above its rising key averages which signal neutral to bullish price action in the near-term.

NEW! Discover a new stock idea each week for less than the cost of 1 trade. CLICK HERE for your Weekly Stock Cheat Sheets NOW!

XOM

5 Best Stocks To Watch For 2014

(Source: Thinkorswim)

Taking a look at the implied volatility (red) and implied volatility skew levels of Exxon Mobil options may help determine if investors are bullish, neutral, or bearish.

Implied Volatility (IV)

30-Day IV Percentile

90-Day IV Percentile

Exxon Mobil Options

21.16%

96%

92%

What does this mean? This means that investors or traders are buying a very significant amount of call and put options contracts, as compared to the last 30 and 90 trading days.

Put IV Skew

Call IV Skew

July Options

Steep

Average

August Options

Steep

Average

As of today, there is an average demand from call buyers or sellers and high demand by put buyers or low demand by put sellers, all neutral to bearish over the next two months. To summarize, investors are buying a very significant amount of call and put option contracts and are leaning neutral to bearish over the next two months.

On the next page, let’s take a look at the earnings and revenue growth rates and the conclusion.

E = Earnings Are Increasing Quarter-Over-Quarter

Rising stock prices are often strongly correlated with rising earnings and revenue growth rates. Also, the last four quarterly earnings announcement reactions help gauge investor sentiment on Exxon Mobil’s stock. What do the last four quarterly earnings and revenue growth (Y-O-Y) figures for Exxon Mobil look like and more importantly, how did the markets like these numbers?

2013 Q1

2012 Q4

2012 Q3

2012 Q2

Earnings Growth (Y-O-Y)

6.00%

11.33%

-1.88%

56.42%

Revenue Growth (Y-O-Y)

-12.29%

-5.29%

-7.68%

1.5%

Earnings Reaction

-1.52%

0.07%

0.47%

1.5%

Exxon Mobil has seen increasing earnings and decreasing revenue figures over most of the last four quarters. From these numbers, the markets have generally been pleased with Exxon Mobil’s recent earnings announcements.

NEW! Discover a new stock idea each week for less than the cost of 1 trade. CLICK HERE for your Weekly Stock Cheat Sheets NOW!

P = Excellent Relative Performance Versus Peers and Sector

How has Exxon Mobil stock done relative to its peers, Chevron (NYSE:CVX), BP (NYSE:BP), Royal Dutch Shell (NYSE:RDSA), and sector?

Exxon Mobil

Chevron

BP

Royal Dutch Shell

Sector

Year-to-Date Return

3.72%

10.89%

2.67%

-4.47%

2.79%

Exxon Mobil has been a relative performance leader, year-to-date.

Conclusion

Exxon Mobil is a global provider of essential energy products and services to companies and consumers operating in a multitude of industries. The stock has been steadily chugging higher and is now consolidating slightly below all-time high prices. Over the last four quarters, Exxon Mobil has seen increasing earnings and decreasing revenue figures what have maintained investors generally happy. Relative to its peers and sector, Exxon Mobil has been a year-to-date performance leader. WAIT AND SEE what Exxon Mobil does this coming quarter.

Friday, August 9, 2013

Why Costco Is Poised to Keep Poppin'

Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, discount warehouse giant Costco Wholesale (NASDAQ: COST  ) has earned a coveted five-star ranking.

With that in mind, let's take a closer look at Costco and see what CAPS investors are saying about the stock right now.

Costco facts

 

 

Headquarters (founded)

Issaquah, Wash. (1976)

Market Cap

$47.9 billion

Industry

Hypermarkets and supercenters

Trailing-12-Month Revenue

$104.9 billion

Management

CEO Craig Jelinek (since 2012)

CFO Richard Galanti (since 1985)

Return on Equity (average, past 3 years)

14.2%

Cash/Debt

$6.5 billion / $4.9 billion

Dividend Yield

1.1%

Competitors

Amazon.com

Target

Wal-Mart Stores 

Sources: S&P Capital IQ and Motley Fool CAPS.

On CAPS, 96% of the 4,698 members who have rated Costco believe the stock will outperform the S&P 500 going forward.

Just last week, one of those Fools, TMFTailwind, succinctly summed up the Costco bull case for our community:

Love the business model -- COST leverages its scale to achieve lower prices and draw in customers, then profits off those customers via membership fees. Renewal rates on membership have been stellar AND stable over the business cycle, so COST enjoys strong cash flow visibility. Steady as she goes.   

Costco's low prices haven't just benefited customers -- shareholders have walloped the market, returning 11,000% over the past two decades. However, with prices near all-time highs, is the ride over for Costco investors? To answer that and more, The Motley Fool's compiled a premium research report with in-depth analysis on Costco. Simply click here now to gain instant access to this valuable investor's resource.

Wednesday, August 7, 2013

A Hidden Reason Brady's Future Looks Bright

Here at The Motley Fool, I've long cautioned investors to keep a close eye on inventory levels. It's a part of my standard diligence when searching for the market's best stocks. I think a quarterly checkup can help you spot potential problems. For many companies, products that sit on the shelves too long can become big trouble. Stale inventory may be sold for lower prices, hurting profitability. In extreme cases, it may be written off completely and sent to the shredder.

Basic guidelines
In this series, I examine inventory using a simple rule of thumb: Inventory increases ought to roughly parallel revenue increases. If inventory bloats more quickly than sales grow, this might be a sign that expected sales haven't materialized. Is the current inventory situation at Brady (NYSE: BRC  ) out of line? To figure that out, start by comparing the company's inventory growth to sales growth. How is Brady doing by this quick checkup? At first glance, OK, it seems. Trailing-12-month revenue increased 1.7%, and inventory decreased 6.1%. Comparing the latest quarter to the prior-year quarter, the story looks decent. Revenue shrank 7.8%, and inventory shrank 6.1%. Over the sequential quarterly period, the trend looks healthy. Revenue dropped 5.7%, and inventory dropped 20.2%.

Advanced inventory
I don't stop my checkup there, because the type of inventory can matter even more than the overall quantity. There's even one type of inventory bulge we sometimes like to see. You can check for it by examining the quarterly filings to evaluate the different kinds of inventory: raw materials, work-in-progress inventory, and finished goods. (Some companies report the first two types as a single category.)

A company ramping up for increased demand may increase raw materials and work-in-progress inventory at a faster rate when it expects robust future growth. As such, we might consider oversized growth in those categories to offer a clue to a brighter future, and a clue that most other investors will miss. We call it "positive inventory divergence."

On the other hand, if we see a big increase in finished goods, that often means product isn't moving as well as expected, and it's time to hunker down with the filings and conference calls to find out why.

What's going on with the inventory at Brady? I chart the details below for both quarterly and 12-month periods.

Source: S&P Capital IQ. Data is current as of latest fully reported quarter. Dollar amounts in millions. FY = fiscal year. TTM = trailing 12 months.

Source: S&P Capital IQ. Data is current as of latest fully reported quarter. Dollar amounts in millions. FQ = fiscal quarter.

Let's dig into the inventory specifics. On a trailing-12-month basis, each segment of inventory decreased. On a sequential-quarter basis, each segment of inventory decreased. Brady seems to be handling inventory well enough, but the individual segments don't provide a clear signal. Brady may display positive inventory divergence, suggesting that management sees increased demand on the horizon.

Foolish bottom line
When you're doing your research, remember that aggregate numbers such as inventory balances often mask situations that are more complex than they appear. Even the detailed numbers don't give us the final word. When in doubt, listen to the conference call, or contact investor relations. What at first looks like a problem may actually signal a stock that will provide great returns. And what might look hunky-dory at first glance could actually be warning you to cut your losses before the rest of the Street wises up.

Can your portfolio provide you with enough income to last through retirement? You'll need more than Brady. Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks." Click here for instant access to this free report.

Add Brady  to My Watchlist.

Tuesday, August 6, 2013

Best Financial Stocks To Watch For 2014

Warren Buffett's track record and the performance of his conglomerate�Berkshire Hathaway (NYSE: BRK-B  ) speaks for itself. No can question the high-quality businesses that he has�assembled under one umbrella. AIG (NYSE: AIG  ) , on the other hand, served as a prime example of a low-quality and poorly managed business during the financial crisis.

However, as AIG cleans itself up and looks toward the future, is its stock a more attractive long-term play than Buffett's giant? In this video, Motley Fool financials analysts David Hanson and Matt Koppenheffer debate which stock offers investors the most opportunity.�

Thanks to the savvy of investing legend Warren Buffett, Berkshire Hathaway's book value per share has grown a mind-blowing 586,817% over the past 48 years. But with Buffett aging and Berkshire rapidly evolving, is this insurance conglomerate still a buy today? In The Motley Fool's premium report on the company, Berkshire expert Joe Magyer provides investors with key reasons to buy as well as important risks to watch out for. Click here now for instant access to Joe's take on Berkshire!

Best Financial Stocks To Watch For 2014: ProShares UltraShort S&P500 (SDS)

ProShares UltraShort S&P500 (the Fund), formerly UltraShort S&P500 ProShares, seeks daily investment results that correspond to twice the inverse daily performance of the S&P 500 Index. The S&P 500 Index is a measure of large-cap United States stock market performance. The S&P 500 Index is a capitalization-weighted index of 500 United States operating companies and real estate investment trusts (REITs) selected by an S&P committee through a non-mechanical process that factors criteria, such as liquidity, price, market capitalization, financial viability and public float.

The S&P 500 Index is a price return index. Reconstitution of the Index occurs both on a quarterly and on an ongoing basis. The Fund takes positions in securities and/or financial instruments that, in combination, should have similar daily return characteristics as 200% of the daily return of the index. The Fund�� investment advisor is ProShare Advisors LLC.

Best Financial Stocks To Watch For 2014: Paulson Capital Corp.(PLCC)

Paulson Capital Corp., through its subsidiary, Paulson Investment Company, Inc., operates as a brokerage company principally in the United States. It engages in securities brokerage activities, which include acting as agent for purchase and sale of common and preferred stocks, options, warrants, and debt securities traded on securities exchanges or in the over-the-counter market. The company?s corporate finance activities comprise underwriting initial and follow-on public offerings, private investments in public equity, and private placements for smaller companies; securities trading and market making activities consist of executing trades in equity securities, corporate debt securities, and municipal bonds; and market making activities are conducted with dealers in the wholesale market and its customers. Its investment activities include holding securities for investment, which primarily include securities purchased for investment and underwriter warrants. As of December 31, 2010, the company operated 39 branch offices in California, Colorado, Connecticut, Florida, Georgia, New Jersey, New York, Oregon, Utah, and Washington. Paulson Capital Corp. was founded in 1969 and is based in Portland, Oregon.

Best Clean Energy Stocks To Own For 2014: Royal Bank Of Canada(RY)

Royal Bank of Canada provides personal and commercial banking, wealth management services, insurance, corporate and investment banking, and transaction processing services under the RBC name worldwide. Its Canadian Banking segment offers personal financial services, business financial services, and cards and payment solutions. The company?s Wealth Management segment provides wealth and asset management, and estate and trust services to affluent and high net worth clients through distributors, as well as directly to institutional and individual clients in Canada, the United States, Europe, Asia, and Latin America. Its Insurance segment provides various life and health insurance, including universal life, accidental death and critical illness protection, disability, long-term care insurance, and group benefits; and property and casualty insurance comprising home, auto, and travel insurance, as well as wealth accumulation solutions; and reinsurance products through retail ins urance branches, call centers, independent insurance advisors and travel agencies, financial institutions, and career sales force. The company?s International Banking segment offers various financial products and services to individuals, business clients, and public institutions in the U.S. and Caribbean. This segment also provides global custody, fund and pension administration, securities lending, shareholder services, analytics, and other related services to institutional investors. Royal Bank of Canada?s Capital Markets segment engages in the trading and distribution of fixed income, foreign exchange, equities, commodities, and derivative products for institutional, public sector, and corporate clients; and involves in investment banking, debt and equity origination, advisory services, corporate lending, private equity, and client securitization businesses. The company was founded in 1864 and is headquartered in Toronto, Canada.

Best Financial Stocks To Watch For 2014: Bank Of Virginia(BOVA)

Bank of Virginia provides commercial and retail banking services to small- to medium-sized businesses, professional concerns, and individuals in the greater Richmond metropolitan region, Virginia. It offers a range of deposit services, including interest-bearing and non interest-bearing checking accounts, commercial accounts, savings accounts, individual retirement accounts, daily money market accounts, and longer-term certificates of deposit. The company?s loan portfolio consists of commercial real estate loans, construction and development real estate loans, residential real estate loans, and commercial loans, as well as consumer loans, such as secured and unsecured installment loans, revolving lines of credit, and home equity loans. In addition, it offers other banking services, including safe deposit boxes, cashier?s checks, banking by mail, direct deposit of payroll and social security checks, the U.S. Savings Bonds, and travelers? checks. Further, the company prov ides debit card and credit card services through a correspondent bank as an agent; and lines of credit, telephone banking, and PC/Internet delivery services. As of December 31, 2009, Bank of Virginia had five banking offices located in Chesterfield and Henrico Counties. The company was formerly known as The Community Bank of Virginia. Bank of Virginia was founded in 2002 and is headquartered in Midlothian, Virginia. Bank of Virginia is a subsidiary of Cordia Bancorp Inc.

Best Financial Stocks To Watch For 2014: The Charles Schwab Corporation(SCHW)

The Charles Schwab Corporation, through its subsidiaries, provides securities brokerage, banking, and related financial services to individuals and institutional clients. It offers various brokerage products and services comprising brokerage accounts with check-writing features, debit card, and billpay; individual retirement accounts; retirement plans for small to large businesses; college savings accounts; designated brokerage accounts; equity incentive plan accounts; and margin loans, as well as access to fixed income securities, equity and debt offerings, options, and futures. The company also provides various banking products and services, including checking accounts linked to brokerage accounts, savings accounts, certificates of deposit, demand deposit accounts, first mortgages, home equity lines of credit, and personal loans collateralized by securities. In addition, it offers trust custody services, personal trust reporting services, and administrative trustee servi ces; advisory services comprising separately managed accounts, customized personal advice for tailored portfolios, and planning and portfolio management; and third-party mutual funds, such as no-load mutual funds, proprietary mutual funds, and other third-party mutual funds, as well as mutual fund trading and clearing services to broker dealers. Further, the company offers third-party and proprietary exchange-traded funds; research, analytic tools, performance reports, market analysis, and educational materials; custodial, trading, technology, practice management, trust asset, and other support services to independent investment advisors; and retirement plan recordkeeping and related services, retirement plan trust and custody services, specialty brokerage services, and mutual fund clearing services. It operates primarily in the United States, the United Kingdom, and Hong Kong. The company was founded in 1971 and is headquartered in San Francisco, California.

Advisors' Opinion:
  • [By Derek Hoffman]

    Charles Schwab Corp. (NYSE:SCHW) delivered a profit and met Wall Street’s expectations, AND beat the revenue expectation. Net income increased 15.95% to $189 million (15 cents per diluted share) in the quarter versus a net gain of $163 million in the year-earlier quarter. Revenue rose 4.45% to $1.22 billion from the year-earlier quarter.

    Charles Schwab Corp. reported adjusted net income of 15 cents per share. By that measure, the company met the mean analyst estimate of $0.15. It beat the average revenue estimate of $1.21 billion.

Best Financial Stocks To Watch For 2014: S.Y. Bancorp Inc.(SYBT)

S.Y. Bancorp, Inc. operates as the bank holding company for Stock Yards Bank & Trust Company that provides commercial and personal banking services in Louisville, Kentucky; southern Indiana and Indianapolis, Indiana; and Cincinnati, Ohio. Its deposits consist of non-interest and interest bearing demand deposits, savings deposits, certificates of deposit, individual retirement accounts, money market deposits, and time deposits. The company provides various secured loans, including commercial lines of credit, commercial term loans, real estate, construction, home equity, and consumer loans. It also offers wealth management services, including investment management, trust and estate administration, retirement planning, and financial planning services; securities brokerage services; and life insurance products, as well as originates and sells single-family residential mortgages. As of December 31, 2010, the company had 25 full service banking locations in the Louisville MSA, 2 full service banking locations in Indianapolis, and 3 full service banking locations in Cincinnati. S.Y. Bancorp, Inc. was founded in 1904 and is headquartered in Louisville, Kentucky.